Beta Drugs Limited develops and manufactures oncology formulations, injectable medicines, tablets, capsules, and other specialty pharmaceutical products. The company focuses primarily on affordable cancer therapies for domestic and international markets. Investments in manufacturing quality and regulatory compliance strengthen its competitive position. Rising incidence of chronic diseases continues to increase demand for oncology treatments. Product pipeline expansion remains an important long-term growth driver.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹1,906 cr | ₹510 cr | ₹58 cr | 21.6 | 79.49 | 7.79 | 18.3% | 0.60 | ₹-13 cr | 23.0 | 1.01 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 126 | 16 | 14.78 | — | — | 13.1% |
| Mar 2026 | 94 | 9 | 8.93 | -49.9% | -48.4% | 9.6% |
| Dec 2025 | 87 | 8 | 8.40 | — | — | 9.8% |
| Sep 2025 | 204 | 24 | 47.38 | — | — | 11.8% |
| Mar 2025 | 182 | 18 | 17.81 | — | — | 9.9% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | — Not assessable |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | — Not assessable |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Turtle | ✗ Close above the prior 55-session high · 2,807.90 ✗ Close above the prior 20-session high · 2,233.90 ✗ Close below the prior 20-session low · 1,625.00 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 1 - basing | |
| Graham | ✗ Price at or below the Graham number · Graham number 628.34 ✗ P/E 15 or less · P/E 21.6 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 7.79 ✓ Current ratio 2 or more · 3.10 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 37/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BETA this stock | -16.3 | -29.5 | +28.9 | — | — | — | 21.6 | 7.79 | 18.3 | — | — | 0.60 | 23.0 | 1,906 | 510 | 58 | 79.5 | 1.01 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |